Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122335 | 0.80 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL20782577 | 0.78 | P2RY1 (0.33) | P2RY1 | |
| SCHEMBL17481226 | 0.76 | COMT (0.40) | ALDH1A1POLBHTTP2RY1SMN1; SMN2 | |
| SCHEMBL13019690 | 0.73 | P2RY1 (0.39) | P2RY1 | |
| SCHEMBL8555203 | 0.72 | P2RY1 (0.43) | ALDH1A1P2RY1KMT2ASMN1; SMN2 | |
| SCHEMBL9224524 | 0.72 | P2RY1 (0.43) | ALDH1A1P2RY1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8806645 | 0.72 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL3148442 | 0.72 | — | — | |
| SCHEMBL9501596 | 0.70 | MEN1 (0.34) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20909349 | 0.69 | SMN1; SMN2 (0.34) | P2RY1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6025199-A | — | — | None | — | — | JP | disclosed |
| JP-7149747-A | — | — | None | — | — | JP | disclosed |
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| US-12128106-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2021155317-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2019044868-A1 | PYRIMIDINE DERIVATIVE | あすか製薬株式会社 | 2019-03-07 | — | — | WO | disclosed |
| EP-0566138-B1 | Amino thiazole derivatives and their use as fungicides | HODOGAYA CHEMICAL CO LTD (JP) | 1998-11-18 | — | — | EP | disclosed |
| JP-H07149747-A | THIAZOLE DERIVATIVE | HODOGAYA CHEM CO LTD | 1995-06-13 | — | — | JP | disclosed |
| JP-H0625199-A | THIAZOLE DERIVATIVE | HODOGAYA CHEM CO LTD | 1994-02-01 | — | — | JP | disclosed |
| EP-0566138-A1 | Amino thiazole derivatives and their use as fungicides | HODOGAYA CHEMICAL CO., LTD. (JP) | 1993-10-20 | — | — | EP | disclosed |
| EP-0348737-B1 | HETEROARYLOXY-ACETIC ACID N-ISOPROPYL ANILIDES | BAYER AG (DE) | 1993-08-04 | — | — | EP | disclosed |
| US-5090991-A | HERBICIDAL N-ISOPROPYLHETEROARYLOXYACETANILIDES | BAYER AKATIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| US-4968342-A | PRE-AND POSTEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0348737-A1 | Heteroaryloxy-acetic acid N-isopropyl anilides | BAYER AG (DE) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885CYP1A2 4379/4885POLB 4486/4885 |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885CYP1A2 4379/4885POLB 4486/4885 |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885CYP1A2 4379/4885POLB 4486/4885 |
| US-12128106-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885CYP1A2 4379/4885POLB 4486/4885 |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885CYP1A2 4379/4885POLB 4486/4885 |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885CYP1A2 4379/4885POLB 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.